Research Finds Lower Dose Of BAM Plus ETE Linked To Reduced Incidence Of Persistently High SARS-CoV-2 Viral Load, Greater Reductions In Viral Load Relative To Placebo

Infectious Disease Advisor (10/15, Basilio) reports research found that “a lower dose of the monoclonal antibody therapy combination bamlanivimab (BAM) plus etesevimab (ETE) is associated with significantly reduced incidence of persistently high SARS-CoV-2 viral load and greater reductions in viral load relative to placebo, with a safety profile similar to that of higher doses of the drug combination.” The investigators said “infusions of over ~8 min did not result in meaningful increase in incidence of” treatment-emergent adverse events “compared to higher doses of BAM+ETE administered over 30–60 min.” The findings were published in Infectious Diseases and Therapy.